Cowen and Company’s Pfizer PFE Stock Holding History

Cowen and Company’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-43,952	Closed	-$8K	–	499
2020 Q2	$8K	Sell	43,952 -8,748	-17%	-$297K	﹤0.01%	369
2020 Q1	$1K	Buy	+52,700	New	+$1.8M	﹤0.01%	396

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Cowen and Company's PFE Position: Q1 2022 in Review

Cowen and Company sold out of Pfizer (PFE) in Q1 2022, closing a stake of 98,385 shares — an estimated $5.81M sold.

Cowen and Company first reported a position in PFE in Q3 2020 and held it in 2 quarters. The position peaked at $5.81M in Q4 2021. 3,196 funds tracked by Wall St. Rank hold PFE as of Q1 2022.

Cowen and Company reported no remaining Pfizer position as of Q1 2022 after selling out during the quarter.
Cowen and Company sold 98,385 Pfizer shares in Q1 2022, an estimated $5.81M.
Cowen and Company first reported a position in Pfizer in Q3 2020 and held it in 2 quarters.
Cowen and Company's Pfizer position peaked at $5.81M in Q4 2021.
3,196 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.

Based on Cowen and Company's 13F filing for Q1 2022, filed 16 May 2022.